Novartis to manufacture CureVac’s Covid-19 vaccine candidate CVnCoV
Novartis will manufacture the mRNA and bulk drug product for up to 50 million doses of the CVnCoV vaccine candidate by end of 2021
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Novartis will manufacture the mRNA and bulk drug product for up to 50 million doses of the CVnCoV vaccine candidate by end of 2021
Exscientia intends to use proceeds from the financing round to further advance
The expanded approval is based on CROWN trial, which showed that treatment
FDB intends to create 300 new positions in Denmark by the end
The partnership will integrate DiA Imaging’s AI applications with Philips’ ultrasound technology